Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals. Positive aspects include a 24% revenue increase and cost reduction initiatives, but challenges like declining margins, debt burden, and soft demand in key markets offset them. The Q&A highlighted gross margin improvements and potential growth in Europe, yet concerns about U.S. rescheduling and Polish supply issues persist. Overall, the financial performance and strategic outlook are balanced, leading to a neutral sentiment.
Key Financial Performance
Cannabis net revenue $57 million, up 24% year-over-year. This improvement was driven by strong growth in Canada Medical (13% increase), international market sales (4% increase), and Canada adult-use (43% increase). Reasons include increased distribution, strong consumer demand, and improved supply consistency.
Canada Medical net revenue Grew 13% year-over-year. Reasons include an increase in the number of insured patients, larger order sizes, and a broader assortment of product choices on the Spectrum Therapeutics store.
International market sales Increased 4% year-over-year. Reasons include triple-digit growth in Germany due to improved supply consistency and margin-accretive bulk cannabis sales in Europe. However, this was partially offset by softer sales in Poland due to regulatory changes and supply challenges, and lower sales in Australia due to price compression.
Canada adult-use net revenue Increased 43% year-over-year. Reasons include increased distribution, strong consumer demand for infused pre-rolled joints, flower, and vapes, and improved commercial execution within the retail channel.
Storz & Bickel revenue $15 million, down 25% year-over-year. Reasons include lapping strong sales from a year ago and weaker consumer demand in key markets like the U.S. due to a challenging macroeconomic backdrop.
Cannabis gross margin 24%, down from the prior year. Reasons include higher near-term costs to produce Claybourne infused pre-rolled joints, softer sales in the high-margin Polish market, and price compression in Australia.
Storz & Bickel gross margin 29%, down from 39% last year. Reasons include lower sales and a challenging macroeconomic backdrop.
SG&A expenses Declined 21% year-over-year. Reasons include ongoing cost reduction initiatives, permanent structural changes, and a 15% reduction in SG&A headcount.
Adjusted EBITDA loss $8 million, compared to a loss of $5 million a year ago. Reasons include lower cannabis gross margins and lower Storz & Bickel sales.
Free cash flow Outflow of $12 million, compared to an outflow of $56 million in the same period last year. Reasons include reduced cash used from operating activities and lower cash interest payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Canada Medical Net Revenue: Grew 13%, marking 3 consecutive quarters of growth. Spectrum Therapeutics expanded offerings to enhance patient experience.
Canada Adult-Use Net Revenue: Increased 43% year-over-year, driven by targeted product portfolio and expanded distribution.
Storz & Bickel New Device: Preparing to launch a new vaporizer device to broaden consumer appeal and support performance in the second half of the year.
International Market Growth: International net revenues grew 4%, with Germany delivering triple-digit growth. Bulk sales into the U.K. supported performance, while supply challenges impacted Poland.
European Market Strategy: Appointed Miles Worne as Managing Director to strengthen market routes, ensure supply consistency, and build infrastructure for long-term leadership.
Cost Reduction Initiatives: Achieved $17 million in annualized savings, reaching 85% of the $20 million target.
Gross Margin Improvement: Actions underway include price adjustments, automation, and new product registrations to drive margin improvement.
Focus on U.S. Market: Continued focus on U.S. cannabis market as a long-term opportunity. Acreage secured $20 million in funding, and Wana expanded CBD beverage distribution.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Compressed Margins: The company is facing pressure on gross margins, which is fundamental to strengthening the balance sheet, achieving positive EBITDA, and unlocking future growth. Actions are being taken to address this issue, but it remains a significant challenge.
Storz & Bickel Revenue Decline: Revenue for the Storz & Bickel segment was down 25% year-over-year due to weaker consumer demand and spending in key markets like the U.S. This decline is attributed to a challenging macroeconomic backdrop and reduced sales of premium devices.
Supply Challenges in Europe: Supply challenges temporarily impacted results in Poland, and operational improvements to increase cannabis supply into Europe are still ongoing, expected to conclude in Q3.
Regulatory Changes in Poland: Regulatory changes limiting online prescriptions in Poland have negatively impacted sales in the region.
Price Compression in Australia: Lower sales in Australia were driven by increasing supply in the market, resulting in price compression.
High Production Costs for Claybourne Pre-Rolls: Higher near-term costs to produce Claybourne infused pre-rolled joints due to additional labor and third-party partners to meet demand have negatively impacted margins.
Debt and Interest Payments: The company has a debt balance of $295 million and is working on prepayments to reduce interest expenses. However, this remains a financial burden.
Soft Consumer Demand in Key Markets: Weaker consumer demand and spending in key markets like the U.S. have impacted sales, particularly in the Storz & Bickel segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future growth in European markets: Operational improvements to increase cannabis supply into Europe are expected to conclude in Q3, supporting top-line acceleration and margin accretion in the back half of the year. New product registrations aimed at increasing strain availability and supply in Germany and Poland are expected to drive growth in the second half of fiscal '26.
Canada adult-use market: Sustained top-line performance is expected over the remaining quarters of fiscal '26, driven by increased distribution, improved commercial execution within the retail channel, and continued strong consumer demand for new products, including infused pre-rolls, all-in-one vapes, and new flower offerings.
Storz & Bickel segment: A new device launch in the coming weeks is expected to broaden consumer appeal and support improved performance in the second half of the year. Top-line growth and gross margin improvements are anticipated over the course of fiscal '26.
Cost reduction initiatives: The company has already achieved $17 million in annualized savings against a $20 million target and is looking for additional efficiencies. These measures are expected to improve gross margins and support positive adjusted EBITDA.
Free cash flow improvement: Significant improvement in free cash flow is expected for fiscal '26, driven by reduced cash interest costs, improved working capital management, and lower capital expenditures.
U.S. market opportunities: Momentum continues to build for rescheduling and legalization. Acreage has secured $20 million in funding, and other U.S. operations are focusing on cost reductions and expanding distribution.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you speak to the drivers behind the sequential improvement in gross margin, particularly in cannabis, and how it might have been broken out between international and Canadian?
A:Management highlighted that gross margin is a key focus area, with expectations to exit the year with margins in the low to mid-30s. Improvements are driven by efficiency measures like expanding production capacity, reducing temporary labor costs, and prioritizing supply to profitable markets. The improvements seen in Q1 were expected, with continued progress anticipated in the second half of the year.
Q:Can you elaborate on the supply challenges in Poland and whether the situation has normalized?
A:Management acknowledged supply challenges in Poland, attributing them to internal flower allocation processes. These processes have now been implemented, and the company expects to return to growth in the Polish market soon.
Q:What are the 2 or 3 other European markets Canopy Growth is excited about in the next 2-3 years, and is everything sold in Europe Canopy Growth product?
A:Management emphasized their focus on Germany and Poland as near-term opportunities, with plans to develop infrastructure and strategy for broader European growth. They recently hired a Managing Director for Europe to lead these efforts. Most of the products sold in Europe are grown in Canada.
Q:What momentum do you see for rescheduling in the U.S., and why are the prospects better today?
A:Management did not comment directly on rescheduling prospects but noted demand increases in select U.S. geographies and infrastructure developments that allow for profitable operations ahead of rescheduling. They expressed confidence in the work being done by the CEO of CUSA and his team to position the company well for potential rescheduling.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about U.S. rescheduling prospects, providing only general comments about demand increases and infrastructure developments without addressing the likelihood or timing of rescheduling.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACRES CCELL
Aaron Grey
Acreage USD
Acreage divestiture
Associates Kirk
Bickel segment
Blood Orange
Burns Director
CBD beverage
CCELL vapes
CEO Director
Canada Medical
Canada adult
Canada quarter
Cannabis way
Canopy Canada
Capital
Carlton Stewart
Choucair
Interim Chief
Markets
Partners
Research Division
Zuanic
building
core offering
digit
distribution sale
function
fundamental
gain
production distribution
progress cost
region
saving
segment production
week
CGC Transcript
Canopy Growth Corporation (WEED:CA) Q4 2026 Earnings Call Transcript
Neutral6-15
Canopy Growth Corporation (WEED:CA) Q3 2026 Earnings Call Transcript
Unknown2-6
The earnings call presents a mixed picture: positive elements include a 22% increase in international cannabis revenue and reduced SG&A expenses. However, concerns arise from declining gross margins and unclear guidance on achieving positive EBITDA. The Q&A reveals uncertainties about veteran pricing impacts and cash utilization. The absence of a clear market cap further complicates predictions. Overall, the sentiment is balanced, resulting in a neutral outlook for the stock price movement over the next two weeks.
Canopy Growth Corporation (WEED:CA) Q2 2026 Earnings Call Transcript
Positive11-7
The earnings call revealed strong financial performance in the Canadian market and improved adjusted EBITDA. Cost reduction initiatives and free cash flow improvement are positive indicators, despite some challenges in international markets. The Q&A highlighted strategic focus on cost management and potential market growth in Europe and the U.S., with no major capital investments needed. The sentiment is positive, driven by operational improvements and market expansion plans, likely resulting in a stock price increase of 2% to 8%.
Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript
Unknown8-8
The earnings call reflects mixed signals. Positive aspects include a 24% revenue increase and cost reduction initiatives, but challenges like declining margins, debt burden, and soft demand in key markets offset them. The Q&A highlighted gross margin improvements and potential growth in Europe, yet concerns about U.S. rescheduling and Polish supply issues persist. Overall, the financial performance and strategic outlook are balanced, leading to a neutral sentiment.
CGC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
